ibrutinib,zanubrutinib
abbvie,beigene,janssen
['zanubrutinib', 'cll', ' ibru', 'alpine']
christine sadlowski talks to dr. jennifer r. brown about results from the phase 3 alpine study, which favored the second-generation bruton s tyrosine kinase inhibitor zanubrutinib over ibrutinib for relapsed/refractory cll/sll. #ash22 
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.